Skip to main content

Advertisement

Log in

Cancer incidence in Spain, 2015

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

Periodic cancer incidence estimates of Spain from all existing population-based cancer registries at any given time are required. The objective of this study was to present the current situation of cancer incidence in Spain.

Methods

The Spanish Network of Cancer Registries (REDECAN) estimated the numbers of new cancer cases occurred in Spain in 2015 by applying the incidence-mortality ratios method. In the calculus, incidence data from population-based cancer registries and mortality data of all Spain were used.

Results

In 2015, nearly a quarter of a million new invasive cancer cases were diagnosed in Spain, almost 149,000 in men (60.0%) and 99,000 in women. Globally, the five most common cancers were those of colon–rectum, prostate, lung, breast and urinary bladder. By gender, the four most common cancers in men were those of prostate (22.4%), colon–rectum (16.6%), lung (15.1%) and urinary bladder (11.7%). In women, the most common ones were those of breast (28.0%), colon–rectum (16.9%), corpus uteri (6.2%) and lung (6.0%). In recent years, cancer incidence in men seems to have stabilized due to the fact that the decrease in tobacco-related cancers compensates for the increase in other types of cancer like those of colon and prostate. In women, despite the stabilization of breast cancer incidence, increased incidence is due, above all, to the rise of colorectal and tobacco-related cancers.

Conclusion

To reduce these incident cancer cases, improvement of smoking control policies and extension of colorectal cancer screening should be the two priorities in cancer prevention for the next years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Source: Spanish Network of Cancer Registries (REDECAN)

Fig. 2

Source: Spanish Network of Cancer Registries (REDECAN)

Fig. 3

Source: Spanish Network of Cancer Registries (REDECAN)

Fig. 4

Source: Spanish Network of Cancer Registries (REDECAN)

Fig. 5

Source: Spanish Network of Cancer Registries (REDECAN)

Fig. 6

Source: Spanish Network of Cancer Registries (REDECAN)

Similar content being viewed by others

References

  1. Instituto Nacional de Estadística. Defunciones según la Causa de Muerte. Madrid: Instituto Nacional de Estadística. 2014 [updated 2016]. http://www.ine.es/jaxi/Tabla.htm?path=/t15/p417/a2014/l0/&file=01004.px&L=0. Accessed 3 Oct 2016.

  2. Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG. Cancer registration: principles and methods. Lyon: IARC Sci Publ No. 95; 1991.

    Google Scholar 

  3. Moreno V, González JR, Soler M, Bosch FX, Kogevinas M, Borràs JM. Estimación de la incidencia de cáncer en España: período 1993–1996. Gac Sanit. 2001;15(5):380–8.

    Article  CAS  PubMed  Google Scholar 

  4. López-Abente G, Pollán M, Aragonés N, Pérez B, Gómez B, Hernández Barrera V, et al. Situación del cáncer en España: Incidencia. An Sist Sanit Navar. 2004;27(2):165–73.

    Article  PubMed  Google Scholar 

  5. Sanchez MJ, Payer T, de Angelis R, Larrañaga N, Capocaccia R, Martinez C. Cancer incidence and mortality in Spain: estimates and projections for the period 1981–2012. Ann Oncol. 2010;21(Suppl 3):iii30–6.

    PubMed  Google Scholar 

  6. International Agency for Research on Cancer. EUCAN. Lyon: International Agency for Research on Cancer [updated 2012]. http://eco.iarc.fr/EUCAN/Default.aspx. Accessed 3 Oct 2016.

  7. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr.

  8. Navarro C, Martos C, Ardanaz E, Galceran J, Izarzugaza I, Peris-Bonet R, et al. Population-based cancer registries in Spain and their role in cancer control. Ann Oncol. 2010;21(Suppl 3):iii3–13.

    PubMed  Google Scholar 

  9. World Health Organization. International Statistical classification of diseases and related health problems. 10th revision. Geneva: WHO; 1992.

    Google Scholar 

  10. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer. 2002;38(1):99–166.

    Article  CAS  PubMed  Google Scholar 

  11. Møller B, Fekjær H, Hakulinen T, Sigvaldason H, Storm HH, Talbäck M, et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Stat Med. 2003;22:2751–66.

    Article  PubMed  Google Scholar 

  12. R Core Team. 2013. http://cran.r-project.org/web/packages/BRugs/index.html; http://cran.r-project.org/web/packages/R2WinBUGS/index.html; http://www.openbugs.net. Accessed 3 Oct 2016.

  13. Rapiti E, Guarnori S, Pastoors B, Miralbell R, Usel M. Planning for the future: cancer incidence projections in Switzerland up to 2019. BMC Public Health. 2014;14:102.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Rébillard X, Grosclaude P, Leone N, Velten M, Coureau G, Villers A, et al. Incidence and mortality of urological cancers in 2012 in France. Prog Urol. 2013;23(Suppl 2):S57–65.

    Article  PubMed  Google Scholar 

  15. Ascunce N, Salas D, Zubizarreta R, Almazán R, Ibáñez J, Ederra M. Cancer screening in Spain. Ann Oncol. 2010;21(Suppl 3):iii43–51.

    PubMed  Google Scholar 

  16. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents, vol. VIII. Lyon, France: IARC Sci Publ 155; (2002) http://www.iarc.fr/en/publications/pdfs-online/epi/sp155/.

  17. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. Cancer incidence in five continents, vol IX. Lyon, France: IARC Sci Publ 160; (2007) http://www.iarc.fr/en/publications/pdfs-online/epi/sp160/.

  18. Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, et al., editors. Cancer incidence in five continents, vol. X (electronic version) Lyon: IARC; (2013) http://ci5.iarc.fr. Accessed 6 June 2016 (printed version: IARC Scientific Publication No. 164, 2014).

  19. Bashir S, Estève J. Analysing the difference due to risk and demographic factors for incidence or mortality. Int J Epidemiol. 2000;29(5):878–84.

    Article  CAS  PubMed  Google Scholar 

  20. Peris R, Felipe S, Valero S, Pardo E. Cáncer infantil en España. Estadísticas 1980–2014. Registro Español de Tumores Infantiles (RETI-SEHOP). Valencia: Universitat de València; 2015. http://www.uv.es/rnti/informes.html (Edición Preliminar, CD-Rom).

  21. Marcos-Gragera R, Mallone S, Kiemeney LA, Vilardell L, Malats N, Allory Y, et al. Urinary tract cancer survival in Europe 1999–2007: results of the population-based study EUROCARE-5. Eur J Cancer. 2015;51:2217–30.

    Article  Google Scholar 

  22. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.

    Article  CAS  PubMed  Google Scholar 

  23. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Tobacco Smoke and Involuntary Smoking, vol. 83. Lyon: IARC; 2004.

    Google Scholar 

  24. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Ionizing radiation, part 1: X- and gamma-radiation, and neutrons, vol. 75. Lyon: IARC; 2000.

    Google Scholar 

  25. Büchner FL, Bueno-de-Mesquita HB, Ros MM, Overvad K, Dahm CC, Hansen L, et al. Variety in fruit and vegetable consumption and the risk of lung cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomark Prev. 2010;19(9):2278–86.

    Article  Google Scholar 

  26. Instituto Nacional de Estadística (INE). Encuesta Nacional de Salud de España. Estudios nacionales de consumo de tabaco 1978–1982. (1978).

  27. Instituto Nacional de Estadística (INE). Encuesta Nacional de Salud 2011–12. [Internet]. Madrid: INE; 2013. http://www.ine.es/metodologia/t15/t153041912.pdf.

  28. Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomark Prev. 2009;18(2):541–50.

    Article  CAS  Google Scholar 

  29. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Part B: biological agents, vol 100B. Lyon: IARC; 2012. http://monographs.iarc.fr/ENG/Monographs/vol100B/index.php.

  30. Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB, Maisonneuve P, et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer. 2008;122(1):155–64.

    Article  CAS  PubMed  Google Scholar 

  31. Vineis P, Pirastu R. Aromatic amines and cancer. Cancer Causes Control. 1997;8:346–55.

    Article  CAS  PubMed  Google Scholar 

  32. Bosetti C, Boffetta P, La Vecchia C. Occupational exposures to polycyclic aromatic hydrocarbons, and respiratory and urinary tract cancers: a quantitative review to 2005. Ann Oncol. 2007;18:431–46.

    Article  CAS  PubMed  Google Scholar 

  33. Mannetje A, Kogevinas M, Chang-Claude J, Cordier S, Gonzalez CA, Hours M, et al. Occupation and bladder cancer in European women. Cancer Causes Control. 1999;10:209–17.

    Article  CAS  PubMed  Google Scholar 

  34. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Part C: arsenic, metals, fibres, and dusts, vol 100C. Lyon: IARC; 2012. http://monographs.iarc.fr/ENG/Monographs/vol100C/index.php.

  35. Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. Alcohol consumption and the risk of cancer: a meta-analysis. Alcohol Res Health. 2001;25(4):263–70.

    CAS  PubMed  Google Scholar 

  36. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Alcohol drinking, vol 38. Lyon: IARC; 1988. http://monographs.iarc.fr/ENG/Monographs/vol1-42/mono38.pdf.

  37. World Cancer Research Fund/American Institute for Cancer Research (AICR). Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007. http://discovery.ucl.ac.uk/4841/.

  38. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375–83.

    Article  CAS  PubMed  Google Scholar 

  39. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology. 1998;114(6):1169–79.

    Article  CAS  PubMed  Google Scholar 

  40. Straif K, Benbrahim-Tallaa L, Baan R, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens—part C: metals, arsenic, dusts, and fibres. Lancet Oncol. 2009;10(5):453–4.

    Article  PubMed  Google Scholar 

  41. Krejs GJ. Gastric cancer: epidemiology and risk factors. Dig Dis. 2010;28(4–5):600–3.

    Article  PubMed  Google Scholar 

  42. López-Abente G, Ardanaz E, Torrella-Ramos A, Mateos A, Delgado-Sanz D, Chirlaque MD, For the Colorectal Cancer Working Group. Changes in colorectal cancer incidence and mortality trends in Spain. Ann Oncol. 2010;21(Suppl 3):iii76–82.

    PubMed  Google Scholar 

  43. Winawer SJ. Natural history of colorectal cancer. Am J Med. 1999;106(1A):3S–6S.

    Article  CAS  PubMed  Google Scholar 

  44. World Cancer Research Fund/American Institute for Cancer Research (AICR). Continuous update project. Colorectal cancer report 2010 summary. Food, nutrition, physical activity and the prevention of cancer [Internet]. AICR; 2011. http://www.dietandcancerreport.org/cancer_resource_center/downloads/cu/CUP_CRC_summary_2011.pdf.

  45. Platz EA, Willett WC, Colditz GA, Rimm EB, Spiegelman D, Giovannucci E. Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes Control. 2000;11(7):579–88.

    Article  CAS  PubMed  Google Scholar 

  46. Fedirko V, Tramacere I, Bagnardi V, Rota M, Scotti L, Islami F, et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. Ann Oncol. 2011;22(9):1958–72.

    Article  CAS  PubMed  Google Scholar 

  47. Hooker CM, Gallicchio L, Genkinger JM, Comstock GW, Alberg AJ. A prospective cohort study of rectal cancer risk in relation to active cigarette smoking and passive smoke exposure. Ann Epidemiol. 2008;18:28–35.

    Article  PubMed  Google Scholar 

  48. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603–13.

    Article  CAS  PubMed  Google Scholar 

  49. García A, Marzo M, Mascort J, Quintero E, García-Alfonso P, López-Ibor C, et al. Prevención del cáncer colorectal. Aten Primaria. 2009;41(3):127–8.

    Article  Google Scholar 

  50. Red de Programas de Cribado de Cáncer. Situación de los Programas de Cribado de Cáncer Colorrectal en España. Red de Programas de Cribado de Cáncer. XV Reunión anual. Pamplona, junio 2012. http://www.programascancerdemama.org/images/archivos/SituacionColon%202012.pdf.

  51. International Agency for Research on Cancer. IARC monographs on the evaluation of carginogenic risks to humans. A review of human carcinogens. Part E: personal habits and indoor combustions, vol 100E. Lyon: IARC; 2012. http://monographs.iarc.fr/ENG/Monographs/vol100E/.

  52. Malka D, Hammel P, Maire F, Rufat P, Madeira I, Pessione F, et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut. 2002;51(6):849–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Tascilar M, van Rees BP, Sturm PD, Tytgat GN, Hruban RH, Goodman SN, et al. Pancreatic cancer after remote peptic ulcer surgery. J Clin Pathol. 2002;55(5):340–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103–23.

    Article  CAS  PubMed  Google Scholar 

  55. Cabanes A, Pérez-Gómez B, Aragonés N, Pollán M, López-Abente G. La situación del cáncer en España, 1975–2006. Madrid: Instituto de Salud Carlos III; 2009.

    Google Scholar 

  56. Reeves GK, Pirie K, Green J, Bull D. Beral V; Million Women Study Collaborators. Reproductive factors and specific histological types of breast cancer: prospective study and meta-analysis. Br J Cancer. 2009;100(3):538–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Schottenfeld D, Fraumeni JF, editors. Cancer epidemiology and prevention. 3rd ed. New York: Oxford University Press; 2006.

    Google Scholar 

  58. Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, et al. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res. 2008;14(9):2861–9.

    Article  CAS  PubMed  Google Scholar 

  59. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception. 1996;54(3 Suppl):1S–106S.

    Google Scholar 

  60. Benet Rodríguez M, Carvajal García-Pando A, García del Pozo J, Alvarez Requejo A, Vega Alonso T. Hormonal replacement therapy in Spain. Med Clin (Barc). 2002;119(1):4–8.

    Article  Google Scholar 

  61. World Cancer Research Fund/American Institute for Cancer Research (AICR). Continuous update project report summary. Food, nutrition, physical activity and the prevention of breast cancer [Internet]. AICR; 2010. http://www.dietandcancerreport.org/cancer_resource_center/downloads/cu/cu_breast_cancer_report_2008_summary.pdf.

  62. Red de Programas de Cribado de Cáncer; 2013. http://www.programascancerdemama.org/images/archivos/Indicadores_proceso_resultados_2011.pdf.

  63. Pollán M, Michelena MJ, Ardanaz E, Izquierdo A, Sánchez-Pérez MJ, Torrella A. Breast Cancer Working Group. Breast cancer incidence in Spain before, during and after the implementation of screening programmes. Ann Oncol. 2010;21(Suppl 3):iii97–102.

    PubMed  Google Scholar 

  64. Puig-Vives M, Pollan M, Rue M, Osca-Gelis G, Saez M, Izquierdo A, et al. Rapid increase in incidence of breast ductal carcinoma in situ in Girona, Spain 1983–2007. Breast. 2012;21(5):646–51.

    Article  CAS  PubMed  Google Scholar 

  65. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120(4):885–91.

    Article  Google Scholar 

  66. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Part A: pharmaceuticals, vol. 100A. Lyon: IARC; 2012.

    Google Scholar 

  67. Kohlmann W, Gruber SB. Lynch síndrome [Internet]. En: Pagon RA, Bird TD, Dolan CR et al, editores. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 2004. http://www.ncbi.nlm.nih.gov/books/NBK1211/.

  68. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609):303–14.

    Article  Google Scholar 

  69. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329–33.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol. 2006;103(3):1122–9.

    Article  CAS  PubMed  Google Scholar 

  71. Larrañaga N, Galceran J, Ardanaz E, Franch P, Navarro C, Sánchez MJ, et al. Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality. Ann Oncol. 2010;21(Suppl 3):iii83–9.

    PubMed  Google Scholar 

  72. Stanford JL, Ostrander EA. Familial prostate cancer. Epidemiol Rev. 2001;23(1):19–23.

    Article  CAS  PubMed  Google Scholar 

  73. Huncharek M, Haddock KS, Reid R, Kupelnick B. Smoking as a risc factor for prostate cancer. A meta-analysis of 24 prospective cohort studies. Am J Public Health. 2010;100:693–701.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Discacciati A, Wolk A. Lifestyle and dietary factors in prostate cancer prevention. Recent Results Cancer Res. 2014;202:27–37.

    Article  CAS  PubMed  Google Scholar 

  75. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273(7):548–52.

    Article  CAS  PubMed  Google Scholar 

  76. Smedby KE, Askling J, Mariette X, Baecklund E. Autoimmune and inflammatory disorders and risk of malignant lymphomas—an update. J Intern Med. 2008;264(6):514–27.

    Article  CAS  PubMed  Google Scholar 

  77. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Part F: chemical agents and related occupations, vol 100F. Lyon: IARC; 2012. http://monographs.iarc.fr/ENG/Monographs/vol100F/.

  78. Marcos-Gragera R, Pollán M, Chirlaque MD, Gumà J, Sánchez MJ, Garau I, For the Non-Hodgkin’s Lymphoma Working Group. Attenuation of the epidemic increase in non-Hodgkin’s lymphomas in Spain. Ann Oncol. 2010;21(Suppl 3):iii90–6.

    PubMed  Google Scholar 

  79. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood. 2003;101(3):822–6.

    Article  CAS  PubMed  Google Scholar 

  80. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet. 2000;355(9199):165–9.

    Article  CAS  PubMed  Google Scholar 

  81. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Part D: radiation, vol 100D. Lyon: IARC; 2012. http://monographs.iarc.fr/ENG/Monographs/vol100D/.

  82. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol. 2002;146(Suppl 61):1–6.

    Article  PubMed  Google Scholar 

  83. Clark LN, Shin DB, Troxel AB, Khan S, Sober AJ, Ming ME. Association between the anatomic distribution of melanoma and sex. J Am Acad Dermatol. 2007;56(5):768–73.

    Article  PubMed  Google Scholar 

  84. Ocaña-Riola R, Martínez-García C, Serrano S, Buendia-Eisman A, Ruiz-Baena C, Canela-Soler J. Population-based study of cutaneous malignant melanoma in the Granada province (Spain), 1985–1992. Eur J Epidemiol. 2001;17(2):169–74.

    Article  PubMed  Google Scholar 

  85. Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control. 2001;12(1):69–82.

    Article  CAS  PubMed  Google Scholar 

  86. Marcos-Gragera R, Vilar-Coromina N, Galceran J, Borras J, Cleries R, Ribes J, et al. Rising trends in incidence of cutaneous malignant melanoma and their future projections in Catalonia, Spain: increasing impact or future epidemic? J Eur Acad Dermatol Venereol. 2010;24(9):1083–8.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank to National Statistics Institute for the provision of data on mortality in Spain.

REDECAN Working Group: Albacete (Antonio Mateos, Enrique Almar), Asturias (José Ramón Quirós, Marcial V. Argüelles, Virginia Menéndez), Canarias (Dolores Rojas, Araceli Alemán), Castellón (Ana Torrella, Consol Sabater, Paloma Botella), Ciudad Real (Matilde Chico, María Ripoll, Cristina Díaz), Infantil de la Comunitat Valenciana (Marisa Vicente, Nieves Fuster, Paloma Botella), Cuenca (José María Díaz, Rosario Jiménez, Ana Isabel Marcos Navarro), Euskadi-Basque Country (Nerea Larrañaga, Joseba Bidaurrazaga, Arantza Lopez-de-Munain), Girona (Rafael Marcos-Gragera, Àngel Izquierdo, Loreto Vilardell), Granada (María José Sánchez, Elena Molina-Portillo, Miguel Rodríguez-Barranco), La Rioja (Josefina Perucha), Mallorca (Paula Franch, Maria Ramos), Murcia (Carmen Navarro, María Dolores Chirlaque, Diego Salmerón), Navarra (Eva Ardanaz, Marcela Guevara, Rosana Burgui), Tarragona (Jaume Galceran, Alberto Ameijide, Marià Carulla, Jàmnica Bigorra), Registro Español de Tumores Infantiles (Rafael Peris Bonet, Elena Pardo).

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to J. Galceran.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standards

The manuscript does not contain clinical studies or patient data.

Funding

This work was supported by the Red de Investigación Temática en Cáncer RD12/0036/0056 (Rafael Marcos-Gragera) and RD12/0036/0053 (R Peris-Bonet and Jaume Galceran).

Additional information

The members of the REDECAN Working Group are listed in Acknowledgements.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Galceran, J., Ameijide, A., Carulla, M. et al. Cancer incidence in Spain, 2015. Clin Transl Oncol 19, 799–825 (2017). https://doi.org/10.1007/s12094-016-1607-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-016-1607-9

Keywords

Navigation